Journal
ANTICANCER RESEARCH
Volume 42, Issue 10, Pages 4667-4678Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.15971
Keywords
Chemotherapy-induced peripheral neuropathy; pain management; target therapy; immunotherapy
Categories
Ask authors/readers for more resources
Chemotherapy-induced peripheral neuropathy is a challenging adverse effect of chemotherapy that significantly affects patients' quality of life. Despite various treatment approaches, there is currently no standardized treatment. Therefore, finding effective therapies is necessary.
Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse effect of anticancer drugs used in chemotherapy. The disorder may require a chemotherapy dose reduction and a cessation of administration of chemotherapeutic drugs. Its principal sensory symptoms include, tingling, and numbness in the hands and feet. Severe pain can be encompassed among clinical manifestations. CIPN affects dramatically the patient's quality of life (QoL). Pain and sensory symptoms may occur for months, or even years after the termination of chemotherapeutic drugs. Although many pharmacological and non-pharmacological therapeutic approaches have been tested to overcome these symptoms, there is currently no standardized treatment for CIPN. According to current guidelines, Duloxetine is the only recommended agent for painful neuropathic symptoms. Therefore, finding effective therapies for CIPN is mandatory. The aim of this review was to dissect CIPN, the target and immunotherapy-based approaches to this disorder, as well as to offer new insights for new therapeutic perspectives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available